This Article Full Text Full Text (PDF) All Versions of this Article: 34/5/1287    most recent 01.STR.0000066308.25088.64v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xu, J. Articles by Gohlke, P. Search for Related Content PubMed PubMed Citation Articles by Xu, J. Articles by Gohlke, P. Related Collections Cerebrovascular disease/stroke Animal models of human disease Apoptosis Acute Cerebral Infarction Acute Stroke Syndromes Behavioral Changes and Stroke Neuroprotectors Transient Ischemic Attacks

(Stroke. 2003;34:1287.)
© 2003 American Heart Association, Inc.

Original Contributions

Chronic Treatment With a Low Dose of Lithium Protects the Brain Against Ischemic Injury by Reducing Apoptotic Death

Jihong Xu, PhD; Juraj Culman, MD; Annegret Blume, PhD; Stephan Brecht, MD Peter Gohlke, PhD

From the Institute of Pharmacology, Christian-Albrechts University of Kiel, Kiel, Germany.

Correspondence to Peter Gohlke, PhD, Institute of Pharmacology, Christian-Albrechts University of Kiel, Hospitalstrasse 4, 24105 Kiel, Germany. E-mail peter.gohlke{at}pharmakologie.uni-kiel.de

Background and Purpose— In vitro and in vivo studies have demonstrated neuroprotective actions of lithium. The present study investigated the effect of a low dose of lithium on infarct volume and neurological outcome as well as on apoptotic and inflammatory processes in rats exposed to focal ischemia.

Methods— Cerebral ischemia was induced by middle cerebral artery occlusion (MCAO) for 90 minutes followed by reperfusion. Lithium (1 mmol/kg) was given subcutaneously daily for 14 days before the onset of MCAO and 2 days thereafter. Blood parameters and cerebral blood flow were assessed before, during, and after MCAO. Rats were examined for neurological deficits 24 and 48 hours after MCAO. Two days after MCAO, the brains were removed for immunohistochemical evaluation of caspase-3, terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL), activated microglia, and the expression of AP-1 proteins (c-Fos and c-Jun). Infarct volume was assessed by cresyl violet staining.

Results— Pretreatment with lithium did not alter cerebral blood flow or blood parameters. Neurological deficits were significantly decreased in rats treated with lithium at 24 and 48 hours after ischemia. Infarct volume was reduced in rats treated with lithium at 48 hours after ischemia. Lithium significantly decreased the ischemia-induced caspase-3 immunoreactivity and TUNEL staining as well as the AP-1 protein expression in the penumbra of the ischemic cortex. No changes in activated microglia were observed.

Conclusions— The present study demonstrates that chronic treatment with lithium at a low dose exhibits neuroprotection in transient focal cerebral ischemia. Antiapoptotic mechanisms are involved in the lithium-induced neuroprotective effects.

Key Words: apoptosis • cerebral ischemia, focal • lithium • microglia • neuroprotection

This article has been cited by other articles:

				Y. Leng, M.-H. Liang, M. Ren, Z. Marinova, P. Leeds, and D.-M. Chuang Synergistic Neuroprotective Effects of Lithium and Valproic Acid or Other Histone Deacetylase Inhibitors in Neurons: Roles of Glycogen Synthase Kinase-3 Inhibition J. Neurosci., March 5, 2008; 28(10): 2576 - 2588. [Abstract] [Full Text] [PDF]

				Y. R. Kim, M. P.A. van Meer, E. Tejima, Y. Murata, J. B. Mandeville, G. Dai, D.-M. Chuang, B. R. Rosen, and E. H. Lo Functional MRI of Delayed Chronic Lithium Treatment in Rat Focal Cerebral Ischemia Stroke, February 1, 2008; 39(2): 439 - 447. [Abstract] [Full Text] [PDF]

				J. H. Shin, S. I. Cho, H. R. Lim, J. K. Lee, Y. A. Lee, J. S. Noh, I. S. Joo, K.-W. Kim, and B. J. Gwag Concurrent Administration of Neu2000 and Lithium Produces Marked Improvement of Motor Neuron Survival, Motor Function, and Mortality in a Mouse Model of Amyotrophic Lateral Sclerosis Mol. Pharmacol., April 1, 2007; 71(4): 965 - 975. [Abstract] [Full Text] [PDF]

				M Brandt-Christensen, K Kvist, F M Nilsson, P K Andersen, and L V Kessing Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: a pharmacoepidemiological study. J. Neurol. Neurosurg. Psychiatry, June 1, 2006; 77(6): 781 - 783. [Abstract] [Full Text] [PDF]

				Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats FASEB J, June 1, 2006; 20(8): 1162 - 1175. [Abstract] [Full Text] [PDF]

				I. Cappuccio, A. Calderone, C. L. Busceti, F. Biagioni, F. Pontarelli, V. Bruno, M. Storto, G. T. Terstappen, G. Gaviraghi, F. Fornai, et al. Induction of Dickkopf-1, a Negative Modulator of the Wnt Pathway, Is Required for the Development of Ischemic Neuronal Death J. Neurosci., March 9, 2005; 25(10): 2647 - 2657. [Abstract] [Full Text] [PDF]